Aurealis Therapeutics and Xbiome enter into a license and collaboration agreement for Aurealis four-in-one diabetic foot ulcer and inflammatory disease cell and gene therapy AUP-16 in Greater China
Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic wounds, and inflammatory disease […]
